-$0.56 Earnings Per Share Expected for Kezar Life Sciences Inc (NASDAQ:KZR) This Quarter

Share on StockTwits

Brokerages expect Kezar Life Sciences Inc (NASDAQ:KZR) to post earnings per share (EPS) of ($0.56) for the current quarter, Zacks reports. Zero analysts have provided estimates for Kezar Life Sciences’ earnings. The lowest EPS estimate is ($0.58) and the highest is ($0.53). Kezar Life Sciences reported earnings of ($0.30) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 86.7%. The business is expected to report its next earnings results on Tuesday, March 24th.

On average, analysts expect that Kezar Life Sciences will report full-year earnings of ($1.89) per share for the current financial year, with EPS estimates ranging from ($1.91) to ($1.87). For the next year, analysts anticipate that the business will report earnings of ($2.13) per share, with EPS estimates ranging from ($2.50) to ($1.50). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Kezar Life Sciences.

Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.48) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.03.

Several research firms recently weighed in on KZR. Cowen restated a “buy” rating on shares of Kezar Life Sciences in a research report on Wednesday, November 6th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Kezar Life Sciences in a research report on Monday, October 21st. Finally, Zacks Investment Research cut shares of Kezar Life Sciences from a “buy” rating to a “hold” rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Kezar Life Sciences presently has an average rating of “Buy” and a consensus target price of $9.13.

A number of institutional investors and hedge funds have recently modified their holdings of KZR. Metropolitan Life Insurance Co NY bought a new position in Kezar Life Sciences in the first quarter worth $89,000. Acadian Asset Management LLC bought a new position in shares of Kezar Life Sciences during the second quarter valued at $107,000. A.R.T. Advisors LLC purchased a new stake in shares of Kezar Life Sciences during the second quarter valued at $112,000. Wells Fargo & Company MN boosted its position in shares of Kezar Life Sciences by 302.5% during the second quarter. Wells Fargo & Company MN now owns 30,878 shares of the company’s stock valued at $238,000 after buying an additional 23,207 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Kezar Life Sciences by 24.3% during the second quarter. Charles Schwab Investment Management Inc. now owns 35,057 shares of the company’s stock valued at $271,000 after buying an additional 6,854 shares during the last quarter. 49.24% of the stock is owned by institutional investors and hedge funds.

Shares of KZR stock traded up $0.26 during trading on Friday, hitting $3.38. The company had a trading volume of 797 shares, compared to its average volume of 156,105. The company has a quick ratio of 16.67, a current ratio of 16.67 and a debt-to-equity ratio of 0.07. The stock’s 50-day moving average is $3.23 and its two-hundred day moving average is $3.99. The stock has a market capitalization of $60.10 million, a price-to-earnings ratio of -1.46 and a beta of 1.08. Kezar Life Sciences has a 52 week low of $2.36 and a 52 week high of $24.16.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

Featured Article: Hedge Funds Explained

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kezar Life Sciences (NASDAQ:KZR)

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.